This collaboration provides clinical validation and cost savings but does not alter Erasca's near-term cash burn or regulatory path. Monitor AURORAS-1 enrollment and early efficacy data for read-through on ERAS-0015's potential. The stock may see a modest positive reaction on partnership credibility, but no fundamental change.
ERAS drugs
ERAS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 11 $10.44entry
- T+1 · 6mo ago −0.57%α −0.44% · $10.38
- T+5 · 6mo ago −1.63%α −1.54% · $10.27
- T+20 · 5mo ago +28.45%α +28.75% · $13.41
- T+60 · 3mo ago +78.35%α +73.96% · $18.62
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Erasca announced a clinical trial collaboration with Merck to evaluate its pan-RAS molecular glue ERAS-0015 in combination with KEYTRUDA for RAS-mutant solid tumors. Merck will supply pembrolizumab at no cost, and Erasca will sponsor the AURORAS-1 study. This is a non-financial collaboration that provides validation for Erasca's pipeline but does not change the company's fundamental outlook.
Key Facts
- Erasca entered a clinical trial collaboration and supply agreement with Merck for ERAS-0015 + KEYTRUDA in RAS-mutant solid tumors.
- Merck is supplying pembrolizumab at no cost; Erasca sponsors the AURORAS-1 study.
- ERAS-0015 is an oral pan-RAS molecular glue with early Phase 1 data showing favorable safety and partial responses at doses as low as 8 mg QD.
- Approximately 2.7 million patients are diagnosed annually with RAS-mutant tumors worldwide.
- No financial terms of the agreement were disclosed.
Financial Impact
No financial terms disclosed; Merck's supply of pembrolizumab at no cost reduces Erasca's trial expenses modestly.
Risk Factors
- ERAS-0015 is still in early Phase 1; clinical failure remains a significant risk.
- Revolution Medicines has alleged patent infringement regarding ERAS-0015, which could lead to litigation delays.
- Combination trial may not show additive benefit over monotherapy or existing standards.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291730 |
Track record
26 reports on ERAS
4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +95.35% at T+60 after the Apr 27, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $15.21 Now $15.11 −0.66% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.31 Now $15.11 −1.31% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.35 Now $15.11 −1.56% settles Feb 12
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $15.66 Now $15.11 −3.51% settles Feb 11
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $14.64 Now $15.11 +3.21% settles Feb 1
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $13.39 Now $15.11 +12.85% settles Jan 13
- Aug 24, 202612w ago 8-K Bullish 5/10 Entry $17.60 Now $15.11 −14.15% settles Nov 17
- Aug 17, 202613w ago 144 Neutral 3/10 Entry $18.28 to $15.61 Now $15.11 −17.34% ▼ −14.61% −11.84% vs SPY
- Aug 13, 202613w ago Institutional Cluster Bullish 6/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
- Aug 12, 202613w ago 3 Neutral 2/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers